• H Rosner, L Rubin, and A Kestenbaum.
• Department of Anesthesiology, New York Hospital, Cornell Medical Center, New York 10021, USA.
• Clin J Pain. 1996 Mar 1;12(1):56-8.

ObjectiveThis is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain.DesignA case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects.SettingAn outpatient pain management center located within a major university medical center.PatientsConvenience sample of patients referred for management of intractable neuropathic pain.InterventionsSimplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses.Main Outcome MeasuresPatient self-reports and pain scores in successive office visits.ResultsGabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.

32 keywords...

hide…